Inventor · disambiguated record
Yong-Liang Zhu
Also filed as: ZHU YONG · ZHU YONG H · ZHU YONG-LIANG
37 granted patents·23 pending applications·585 citations·filing 2002–2023
98Inventor score
Top patents by PatentIndex Score
60 records- 0199US9469640B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2016·Granted Oct 18, 2016·44 cites·12 claims
- 0298US11304957B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2020·Granted Apr 19, 2022·4 cites·6 claims
- 0398US8415469B2Compounds and methods for kinase modulation, and indications thereforIBRAHIM PRABHA N·Filed 2009·Granted Apr 9, 2013·84 cites·18 claims
- 0497US11865120B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2022·Granted Jan 9, 2024·2 cites·14 claims
- 0597US10172868B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Jan 8, 2019·10 cites·25 claims
- 0697US9849139B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2016·Granted Dec 26, 2017·12 cites·40 claims
- 0797US9844539B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2016·Granted Dec 19, 2017·20 cites·30 claims
- 0897US9550770B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2014·Granted Jan 24, 2017·15 cites·28 claims
- 0997US7504509B2Compounds and methods for development of Ret modulatorsPLEXXIKON INC·Filed 2004·Granted Mar 17, 2009·153 cites·39 claims
- 1096US8067434B2Compounds and methods for development of Ret modulatorsIBRAHIM PRABHA·Filed 2008·Granted Nov 29, 2011·112 cites·10 claims
- 1195US10653701B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2018·Granted May 19, 2020·7 cites·22 claims
- 1295US9572808B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2015·Granted Feb 21, 2017·13 cites·11 claims
- 1395US9249111B2Substituted quinoxalines as B-RAF kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·35 claims
- 1493US9249110B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2012·Granted Feb 2, 2016·13 cites·40 claims
- 1592US10947201B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Mar 16, 2021·6 cites·15 claims
- 1692US10426760B2Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2018·Granted Oct 1, 2019·6 cites·52 claims
- 1791US9518029B2Certain chemical entities, compositions, and methodsQIAN XIANGPING·Filed 2012·Granted Dec 13, 2016·10 cites·33 claims
- 1890US12403145B2Substituted quinazolines for inhibiting kinase activityNEUPHARMA INC·Filed 2023·Granted Sep 2, 2025·0 cites·20 claims
- 1990US10544106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Jan 28, 2020·7 cites·27 claims
- 2089US9688635B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 27, 2017·10 cites·23 claims
- 2189US9295671B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerZHU YONG-LIANG·Filed 2012·Granted Mar 29, 2016·14 cites·24 claims
- 2288US9670180B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2013·Granted Jun 6, 2017·9 cites·53 claims
- 2387US11208388B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Dec 28, 2021·2 cites·17 claims
- 2486US10065932B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Sep 4, 2018·3 cites·22 claims
- 2586US9822081B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2016·Granted Nov 21, 2017·3 cites·20 claims
- 2684US9725421B2Substituted quinoxalines as B-raf kinase inhibitorsNEUPHARMA INC·Filed 2013·Granted Aug 8, 2017·6 cites·24 claims
- 2782US10137125B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2017·Granted Nov 27, 2018·2 cites·26 claims
- 2882US10047059B2Substituted quinoxalines for inhibiting kinase activityNEUPHARMA INC·Filed 2017·Granted Aug 14, 2018·3 cites·20 claims
- 2980US2021353602A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2021·Application pending·0 cites
- 3080US2021346358A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2021·Application pending·0 cites
- 3179US10561652B2Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2019·Granted Feb 18, 2020·1 cites·20 claims
- 3279US2022251049A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
- 3375US2020390763A1Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancerNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 3474US10457641B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2017·Granted Oct 29, 2019·1 cites·22 claims
- 3573US12018002B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Granted Jun 25, 2024·0 cites·15 claims
- 3672US2021040048A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2020·Application pending·0 cites
- 3771US10759766B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2019·Granted Sep 1, 2020·0 cites·20 claims
- 3870US2019209536A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2018·Application pending·0 cites
- 3969US2010190777A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2008·Application pending·0 cites
- 4067US2017319559A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2017·Application pending·0 cites
- 4165US2018111929A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2017·Application pending·0 cites
- 4263US2013303534A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2013·Application pending·0 cites
- 4363US2021163423A1Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2021·Application pending·0 cites
- 4463US2014038948A1Compounds and methods for kinase modulation, and indications thereforWU GUOXIAN·Filed 2013·Application pending·0 cites
- 4560US2016176865A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2015·Application pending·0 cites
- 4660US2012053177A1Compounds and methods for kinase modulation, and indications thereforIBRAHIM PRABHA N·Filed 2011·Application pending·0 cites
- 4759US2013231335A1Inhibitors of polo-like kinaseELAN PHARM INC·Filed 2013·Application pending·0 cites
- 4859US2013331376A1Inhibitors of polo-like kinaseELAN CORP INC·Filed 2013·Application pending·0 cites
- 4958US2015290205A1Compounds and methods for kinase modulation, and indications thereforPLEXXIKON INC·Filed 2015·Application pending·0 cites
- 5056US10590106B2Certain chemical entities, compositions, and methodsNEUPHARMA INC·Filed 2018·Granted Mar 17, 2020·0 cites·21 claims
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Yong-Liang Zhu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →